IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.62
-0.49 (-3.47%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.11
Open14.11
Bid12.50 x 1400
Ask15.30 x 1000
Day's Range13.61 - 14.15
52 Week Range9.07 - 21.20
Volume1,344,969
Avg. Volume1,484,885
Market Cap2.106B
Beta (3Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)-1.85
Earnings DateApr 29, 2019 - May 3, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.45
Trade prices are not sourced from all markets
  • Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares
    Simply Wall St.8 days ago

    Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...

  • Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?
    Zacks9 days ago

    Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?

    Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement
    Business Wire10 days ago

    Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc. (Cyclerion) has been declared effective by the U.S. Securities and Exchange Commission (SEC). The Form 10 reflects Ironwood’s plan for a tax-free spin-off of Cyclerion as a publicly-traded company, which is expected to be completed on April 1, 2019. The completion of the separation is set to occur through a distribution to Ironwood shareholders of one share of Cyclerion common stock for every 10 shares of Ironwood common stock held as of the close of business on March 19, 2019, the record date for the distribution.

  • Business Wire17 days ago

    Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 14, 2019 at 2:35 p.m. Eastern Time at The Loews Miami Beach Hotel in Miami. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

  • Business Wire20 days ago

    Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the 39th Annual Cowen Health Care Conference on Monday, March 11, 2019 at 4:10 p.m. Eastern Time at The Boston Marriott Copley Place in Boston. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

  • GlobeNewswire24 days ago

    Recent Analysis Shows Yamana Gold, Broadcom Inc., Atlas Air Worldwide, Hawaiian, H&E Equipment Services, and Ironwood Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering
    Business Wire26 days ago

    Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced that Cyclerion Therapeutics, Inc. (Cyclerion) has entered into an agreement for a private placement of up to $175 million. Final proceeds from this offering are expected to support Cyclerion’s sGC stimulator portfolio for at least two years, including four clinical data readouts expected in the second half of 2019. The financing transaction is anticipated to close in early April, immediately following the completion of Ironwood’s planned tax-free spin-off of Cyclerion to Ironwood shareholders.

  • Business Wirelast month

    Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

  • Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise
    Zackslast month

    Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise

    Ironwood (IRWD) beats on both earnings and sales in the fourth quarter. Shares up.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of IRWD earnings conference call or presentation 13-Feb-19 1:30pm GMT

    Q4 2018 Ironwood Pharmaceuticals Inc Earnings Call

  • Why Ironwood's Shares Climbed 11.7% on Wednesday
    Motley Foollast month

    Why Ironwood's Shares Climbed 11.7% on Wednesday

    The constipation kingpin reported fourth-quarter results that sparked investor interest.

  • Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript

    IRWD earnings call for the period ending December 31, 2018.

  • Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates
    Zackslast month

    Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates

    Ironwood (IRWD) delivered earnings and revenue surprises of 88.24% and 50.70%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Ironwood: 4Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 10 cents. Losses, adjusted for non-recurring costs, came to 2 cents per share. The results surpassed Wall Street expectations. ...

  • Business Wirelast month

    Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

    – Grew 2018 revenue 16% year-over-year to $347 million, driven primarily by U.S. LINZESS® collaboration revenue of $264 million and linaclotide API sales of $70 milli

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    Biotech stocks held steady in the recent week as earnings from the sector continue to trickle in. The week also saw presentations of clinical trial readouts at a couple of conferences. The following are ...

  • Markitlast month

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 10. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $2.53 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline
    Zacks2 months ago

    Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline

    Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid
    Zacks2 months ago

    Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid

    Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.

  • Business Wire2 months ago

    Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call

    Ironwood Pharmaceuticals, Inc. today announced it will host its fourth quarter and full-year 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 13, 2019.

  • Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation
    Business Wire2 months ago

    Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced the filing by Cyclerion Therapeutics, Inc. (Cyclerion) of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). The Form 10 reflects Ironwood’s plan for a tax-free spin-off of Cyclerion as a publicly-traded company, which is on track to be completed in the first half of 2019. “Today’s filing is a critical step toward creating two differentiated, innovative and productive companies, each with promising foundational assets and the opportunity to build industry-leading businesses,” said Peter Hecht, chief executive officer of Ironwood and future chief executive officer of Cyclerion following completion of the planned separation.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Hercules Capital, Alexandria Real Estate Equities, Ironwood Pharmaceuticals, 22nd Century Group, BorgWarner, and Forestar Group — Discovering Underlying Factors of Influence

    NEW YORK, Jan. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Ironwood Commences Phase I Study on IW-6463 for CNS Disorders
    Zacks2 months ago

    Ironwood Commences Phase I Study on IW-6463 for CNS Disorders

    Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.

  • Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation
    Business Wire2 months ago

    Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced the composition of the Ironwood and Cyclerion Therapeutics, Inc. (“Cyclerion”) boards of directors, in connection with the previously announced planned business separation which is on track to be completed in the first half of 2019. Additionally, Ironwood announced that at its 2019 annual meeting of stockholders, the Ironwood board plans to recommend to its shareholders the elimination of its classified board and transition to a single class of directors to be elected annually.